Recent News

ASCO 2018: Weighing Benefits/Risks of Exemestane Therapy in Premenopausal Women With Breast Cancer

FDA Grants Priority Review to Talazoparib for Metastatic Breast Cancer With BRCA Mutation

2018 ASCO: Ribociclib Plus Fulvestrant for Postmenopausal Patients With Advanced Breast Cancer

ASCO 2018: Can Lymph Node Irradiation Improve Outcomes in Breast Cancer?

ASCO 2018: SANDPIPER Trial Studies Novel Combination Therapy for Advanced Breast Cancer

ASCO 2018: TAILORx Shows Most Women With Early-Stage Breast Cancer Can Avoid Chemotherapy

FDA Accepts New Drug Application for Larotrectinib in Treatment of Certain Solid Tumors

ACR and SBI Offer New Guidance for Breast Cancer Screening

Study Finds Link Between Histone Levels and Efficacy of Radiation Therapy

ASCO 2018 Preview: Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

ASBrS 2018: Are Current Genetic Testing Guidelines for Breast Cancer Too Restrictive?

ASBrS 2018: Preventing Lymphedema Related to Breast Cancer

ASBrS 2018: Impact of Screening Mammography on Patient Outcomes in Breast Cancer

ASTRO Issues New Clinical Guideline for Whole-Breast Radiation Therapy

AACR 2018: How Splicing Factors May Impact Breast Cancer Cell Mitosis

ESTRO 37: Quality of Life With Targeted Radiotherapy for Early Breast Cancer

FDA Grants Fast Track Designation to Balixafortide Plus Eribulin for Metastatic Breast Cancer

AACR 2018: Results of the Pan-Gynecologic Molecular Study

Long-Term Patterns of Chemotherapy-Induced Neuropathy in Women With Breast Cancer

Using Metabolomics to Understand Body Mass Index–Breast Cancer Link

EBCC-11: Omission of Sentinel Lymph Node Biopsy in Subset of Patients With Breast Cancer

EBCC-11: Survival Rates After Prophylactic Mastectomy in BRCA-Mutation Carriers

EBCC-11: Predicting Contralateral Breast Cancer Risk in Women With BRCA Mutation

Effect of Dietary Xenoestrogens on Cellular Metabolism in Breast Cancer

Screening Strategies for Women With Increased Breast Density

AACR 2018 Preview: Acquired HER2 Mutations and Resistance to Hormone Therapy for Breast Cancer

ACC 2018: Managing Cardiotoxicity in Patients Receiving Breast Cancer Chemotherapy

FDA Authorizes First Direct-to-Consumer Test That Reports Mutations in Breast Cancer Genes

Risk of Cardiovascular Diseases in Patients With Breast Cancer

Cancer Survivorship Symposium: Exercise and Arm Mobility After Breast Cancer Surgery

FDA Expands Approval of Abemaciclib to Initial Treatment of Advanced Breast Cancer

Survival Rates and BRCA Status in Younger Women With Breast Cancer

Predictors of Prognosis Discovered in Triple-Negative Breast Cancer

Researchers Evaluate the Need for Breast Biopsies After Treatment for Early Breast Cancer

Two Genes May Link Lynch Syndrome and Breast Cancer

Smoking and Risk of Breast Cancer

Tumor-Infiltrating Lymphocytes and Breast Cancer Prognosis

Novel Treatment Studied in Triple-Negative Breast Cancer

Chemotherapy-Free Combination Regimen in HER2-Positive Breast Cancer

AACR Obesity and Cancer Conference: Breast Cancer Risk in Postmenopausal Women With Normal BMI

Physical Activity May Lead to Better Sleep Quality in Breast Cancer Survivors

Soy and Cruciferous Vegetable Intake in Female Breast Cancer

Neoadjuvant Combination Therapy in Early-Stage Triple-Negative Breast Cancer

Role of Olaparib in HER2-Negative Metastatic Breast Cancer Under Study

Neoadjuvant Trial of Dual HER2 Targeting Plus Lapatinib

Overall Survival Results From Early Breast Cancer TEXT and SOFT Trials

FDA Grants Expanded Approval to Olaparib for BRCA-Mutant Metastatic Breast Cancer

Long-Term Weekly Paclitaxel vs. Nab-paclitaxel or Ixabepilone as First-Line Therapy for Metastatic Breast Cancer

Phase III Trial Investigates Atezolizumab in Triple-Negative Breast Cancer

Substituting Nab-paclitaxel for Paclitaxel in Invasive Breast Cancer

Primary Endocrine Therapy for Estrogen Receptor–Positive Ductal Carcinoma in Situ

FDA Grants Breakthrough Therapy Designation to Ribociclib in Combination Therapy for Advanced Breast Cancer

Potential Role of Abemaciclib in Prognostic Breast Cancer Subgroups

FDA Grants Clearance to Noninvasive Stereotactic Radiotherapy System for Breast Cancer

FDA Approves Pertuzumab Combination Therapy for HER2-Positive Breast Cancer

SABCS 2017: Enzalutamide and Exemestane in Hormone Receptor–Positive Breast Cancer

SABCS 2017: Treatment With GnRHa and Ovarian Function in Women Receiving Chemotherapy for Breast Cancer

SABCS 2017: Duration of Zoledronate Treatment After Adjuvant Chemotherapy

SABCS 2017: Sacituzumab Govitecan as Late Therapeutic Option in Metastatic Breast Cancer

SABCS 2017: Increasing the Dose Intensity of Chemotherapy for Breast Cancer

SABCS 2017: Can Perioperative Aromatase Inhibitor Treatment Predict Long-Term Outcomes in Early Breast Cancer?

SABCS 2017: Shorter vs. Longer Duration Postadjuvant Anastrozole in HER2-Positive Breast Cancer

SABCS 2017: Extended Trastuzumab Treatment in Early-Stage HER2-Positive Breast Cancer

SABCS 2017: First-Line Ribociclib and Endocrine Therapy in Advanced Breast Cancer

SABCS 2017: Tamoxifen Plus Ovarian Function Suppression Regimen for Early Breast Cancer

Combining Focused Ultrasound and Immunotherapy to Treat Breast Cancer

Effect of Pomegranate Extract on Breast Cancer Stem Cells

FDA Approves Biosimilar to Trastuzumab for HER2-Positive Breast Cancer

Outcomes With Regional Anesthesia in Breast Cancer Surgery

Intermittent Versus Continuous Chemotherapy Scheduling in Metastatic Breast Cancer

Benefits Reported for Breast Cancer Patients Who Regularly Practice Yoga

Influence of Race, Insurance Status, and Accessibility on Immediate Breast Reconstruction Rates

Combination of Alisertib and TAK-228 in Triple-Negative Breast Cancer

New Indication for Fulvestrant in Combination Therapy for Advanced Breast Cancer

AORTIC 2017: Are Skin Lighteners and Hair Relaxers Associated With Increased Risk of Breast Cancer?

First-Line Ribociclib and Letrozole in Advanced Breast Cancer

Are Standard-of-Care Treatments in Clinical Trials Really ‘Standard’?

AACR-NCI-EORTC 2017: Potential of Antibiotic Salinomycin in Breast Cancer

CoBrCa 2017: Ovarian Function Suppression Plus AI in Young Women at Risk of Breast Cancer Recurrence

AACR-NCI-EORTC 2017: Potential Novel Agent for Estrogen Receptor–Positive Breast Cancer

CoBrCa 2017: Genetic Testing for Women With Breast Cancer

ACS 2017: Can Socioeconomic Status Predict Quality of Life in Breast Cancer Survivors?

ACS 2017: Women at Higher Risk of Breast Cancer and MRI Screening

Intravenous Rolapitant Approved by FDA for Delayed Chemotherapy-Induced Nausea and Vomiting

FDA Grants Priority Review for Olaparib in Metastatic Breast Cancer

Novel Strategies for Preventing Chemotherapy-Induced Peripheral Neuropathy

Fertility Preservation in BRCA-Positive Women With Breast Cancer

Priority Review Granted by FDA for Abemaciclib as First-Line Treatment for Advanced Breast Cancer

Further Efficacy Outcomes From OlympiAD Trial of Olaparib in Advanced Breast Cancer

ASTRO 2017: Biologic Markers of Primary Breast Cancer and Brain Metastases

ASTRO 2017: Neoadjuvant Radiation Therapy Before Surgery in Locally Advanced Breast Cancer

Priority Review Granted for Adjuvant Combination Treatment for HER2-Positive Breast Cancer

TIL Levels and Response to Pembrolizumab in Metastatic Triple-Negative Breast Cancer

ASTRO 2017: Stereotactic Radiosurgery for Brain Metastases From Breast Cancer

FDA Approves Abemaciclib for Treatment of Breast Cancers That Progress With Endocrine Therapy

ASTRO 2017: Accelerated Breast Radiation Therapy After Mastectomy

ASTRO 2017: Shorter Course of Radiation Therapy for Younger Women With Breast Cancer

Tumor Microenvironment in Racially Distinct Triple-Negative Breast Cancers

ESMO 2017: Neoadjuvant Letrozole Plus Palbociclib in Luminal Breast Cancer

ESMO 2017: Comparison of Biosimilar ABP 980 and Trastuzumab in HER2-Positive Breast Cancer

ESMO 2017: Extended Adjuvant Neratinib for Early-Stage HER2-Positive Breast Cancer

ESMO 2017: Comparison of Two Adjuvant Therapies for Early Breast Cancer

ESMO 2017: Neoadjuvant Combination Therapy With Taselisib and Letrozole in Early Breast Cancer

ESMO 2017: Adding Abemaciclib to Endocrine Therapy for Advanced Breast Cancer

ESMO 2017: Nivolumab After Induction Therapy in Triple-Negative Breast Cancer

ESMO 2017: Adding Everolimus to Letrozole in Metastatic Breast Cancer Therapy

ESMO 2017: Chemotherapy for Small Node-Negative Breast Tumors

Impact of Surgical Modality on Breast-Specific Sensuality

Triple-Negative Breast Cancer: Genomic Metrics and Immune Infiltration

Mammography Device With Option for Patient-Assisted Compression Cleared by FDA

DS-8201 Granted Breakthrough Therapy Designation for HER2-Positive Metastatic Breast Cancer

FDA Approves Expanded Use of Fulvestrant as Monotherapy in Breast Cancer

Neoadjuvant Radiotherapy for Early-Stage Breast Cancer

ASCO Breast Cancer Guideline Update on Use of 70-Gene Test

Nipple-Sparing Mastectomy and Breast Cancer Recurrence

Risk-Reducing Mastectomy vs. Surveillance for Women With BRCA Mutation and History of Ovarian Cancer

Ado-trastuzumab Emtansine as First-Line Therapy for Metastatic Breast Cancer in MARIANNE Trial

Patient-Reported Outcomes in Relation to Fat Grafting in Postmastectomy Breast Reconstruction

Recent Trends in Male Breast Cancer

Leading Cause of Death in Patients With Breast Cancer

Neratinib Approved by FDA for Extended Adjuvant Treatment of HER2-Positive Breast Cancer

ASCO 2017: Ado-trastuzumab Emtansine in Resistant HER2-Positive Breast Cancer

Priority Review Granted for Abemaciclib in Advanced Breast Cancer

ASCO 2017: First-Line Addition of Bevacizumab to Endocrine Therapy in Advanced Breast Cancer

ASCO 2017: Dual HER2 Blockade in Metastatic Breast Cancer

ASCO 2017: Duration of Adjuvant Trastuzumab for HER2-Positive Breast Cancer

Implementing BRCA1/2 Genetic Testing in Patients With Breast Cancer

ASCO 2017: MONALEESA-2 Update on Combination of Ribociclib and Letrozole

Joint Position Statement on Bone Loss Associated With Aromatase Inhibitors

ASCO 2017: Talazoparib in Metastatic Breast Cancer With a Germline BRCA1/2 Mutation

ASCO 2017: Abemaciclib Plus Fulvestrant in Endocrine-Resistant Breast Cancer

ASCO 2017: Adding a Second HER2 Blocker to Standard of Care in Invasive Breast Cancer

ASCO 2017: Addition of Pembrolizumab to Standard Therapy in High-Risk Breast Cancer

ASCO 2017: Olaparib Monotherapy in Metastatic Breast Cancer

ASCO 2017: Safety of Pregnancy After Breast Cancer

ACOG 2017: Prolonged Tamoxifen vs Oophorectomy in Estrogen Receptor–Positive Breast Cancer

ACOG 2017: Debate Continues Over Timing and Frequency of Breast Cancer Screening

Updated Clinical Practice Guidelines on Integrative Therapies

ASBrS 2017: Is Adjuvant Whole-Breast Radiation Therapy Necessary for Ductal Carcinoma in Situ?

ASBrS 2017: Surgical Resection of Primary Tumors in Stage IV Breast Cancer

FDA Approves Co-Pack of Ribociclib and Letrozole for Metastatic Breast Cancer

IMPAKT 2017: Tumor-Infiltrating Lymphocyte Levels in HER2-Positive Breast Cancer

ASBrS 2017: Practice Patterns in Use of SLND After Neoadjuvant Chemotherapy

IMPAKT 2017: LAR Subtype of Triple-Negative Breast Cancer and CDK4/6 Inhibition

ASBrS 2017: Lumpectomy and Excisional Biopsy in an Outpatient Setting

ASBrS 2017: Risk of Lymphedema Related to Breast Cancer

ASBrS 2017: Contralateral Prophylactic Mastectomy for Ductal Carcinoma in Situ

Use of Dexamethasone Oral Solution in Patients Receiving Treatment for Breast Cancer

Predicting Local Metastases After Neoadjuvant Chemotherapy for Breast Cancer

AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

AACR 2017: Atezolizumab Associated With Survival Benefit in Triple Negative Breast Cancer

Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer

Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial

Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Cancer Patients

Buparlisib Phase III Findings: Glass Half Empty or Half Full?